A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations

Trial Profile

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2018

At a glance

  • Drugs Olaparib (Primary) ; Capecitabine; Eribulin; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OlympiAD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 15 Apr 2018 Results published in an AstraZeneca media release.
    • 15 Apr 2018 According to an AstraZeneca media release, data presented today at the American Association for Cancer Research (AACR) Annual Meeting
    • 03 Apr 2018 According to a Merck AG media release, the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top